Antiviral therapeutics for the pediatric population

Pediatric Emergency Care

Volumn 17, Issue 5, 2001, Pages 369-380

  Arora, A ^a   Magee, L ^a   Peck, J ^a   Singer, J ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Antiviral therapeutics; Recommendations

Indexed keywords

ACICLOVIR; AMANTADINE; ANTIVIRUS AGENT; CIDOFOVIR; FAMCICLOVIR; GANCICLOVIR; OSELTAMIVIR; PENCICLOVIR; PLECONARIL; RIBAVIRIN; RIMANTADINE; VALACICLOVIR; ZANAMIVIR;

ANTIMICROBIAL THERAPY; CHEMOTHERAPY; CHICKENPOX; CHILD; CONTINUING EDUCATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; EPSTEIN BARR VIRUS; HERPES; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; INFLUENZA; INFLUENZA VIRUS A; PEDIATRICS; POPULATION RESEARCH; PRACTICE GUIDELINE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

ANTIVIRAL AGENTS; CHILD; CLINICAL TRIALS; ENTEROVIRUS INFECTIONS; HERPESVIRIDAE INFECTIONS; HUMANS; INFLUENZA, HUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIRUS DISEASES;

EID: 0034767978     PISSN: 07495161     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006565-200110000-00014     Document Type: Review

References (138)

1. Influenza
2. Influenza virus infection in children
3. Prevention of Russian influenza by amantadine
4. Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus
5. Prophylactic amantadine dose and plasma concentration-effect relationships in healthy adults
6. Influenza A prophylaxis with amantadine in a boarding school
7. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A
8. Successful treatment of naturally occurring influenza A/USSR/77 H1N1
9. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine
10. Differential effect of amantadine hydrochloride on the systemic and local immune response to influenza A
11. A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis
12. Clinical applications of antiviral agents for chemophrophylaxis and therapy of respiratory viral infections
13. Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic
14. Effectiveness of rimantadine prophylaxis of children within families
15. Rimantadine prophylaxis in children: A follow-up study
16. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families
17. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine
18. Children with influenza A infection: Treatment with rimantadine
19. Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus
20. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection
21. Efficacy and safety of the neuraminidase inhibitor Zanamivir in the treatment of influenzavirus infections
22. Short-term treatment with Zanamivir to prevent influenza: Results of a placebo-controlled study
23. Coadministration of orally inhaled Zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers
24. Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial
25. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: A randomized controlled trial
26. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor Zanamivir in the treatment of influenza: A randomized, double- blind, placebo-controlled European study
27. Randomised trial of efficacy safety of inhaled Zanamivir in treatment of influenza A and B virus infections
28. Pharmacokinetics of Zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers
29. Safety and efficacy of intravenous Zanamivir in preventing experimental human influenza A virus infection
30. Viral encephalitis
31. Use of the oral neuraminidase inhibitor Oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment
32. Use of the selective oral neuraminidase inhibitor Oseltamivir to prevent influenza
33. Effectiveness of Oseltamivir in preventing influenza in household contacts: A randomized controlled trial
34. Oral Oseltamivir treatment of influenza in children
35. Efficacy and safety of the oral neuraminidase inhibitor Oseltamivir in treating acute influenza: A randomized controlled trial
36. Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery
37. Bacterial coinfection in children hospitalized with respiratory syncytial virus infections
38. Respiratory syncytial virus: A continuing culprit and conundrum
39. Respiratory syncytial virus vaccines: Recent developments
40. Immunoprophylaxis of respiratory syncytial virus disease
41. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview
42. From chimpanzee coryza to palivizumab: Changing times for respiratory syncytial virus
43. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases
44. Prospective follow-up and pulmonary functions from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis
45. Gynecologic and obstetric disorders
46. Herpes simplex meningitis in infancy
47. Herpes simplex virus type 2 meningitis and associated genital lesions in a three-year-old child
48. Disseminated herpes simplex virus infection in a neonate
49. Antiviral therapy of herpes simplex and varicella-zoster virus infections
50. Double-blind placebocontrolled trial of oral acyclovir in first-episode genital herpes simplex virus infection
51. Current status and prospects for oral acyclovir treatment of first episode and recurrent genital herpes simplex virus
52. A randomized, placebocontrolled comparison of oval valacyclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections
53. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection. A multicenter double-blind trial
54. Treatment of primary firstepisode genital herpes simplex virus infections with acyclovir: Results of topical, intravenous and oral therapy
55. A randomized, double-blind, comparative trial comparing high- and standard-dose oral acyclovir for first-episode genital herpes infections
56. Pharyngitis associated with herpes simplex virus in college students
57. Brief report: Herpetic geometric glossitis
58. Cutaneous herpes simplex virus, type I, in association with Staphylococcus aureus in an infant
59. Herpes simplex dissemination following glucocorticoids for upper airway obstruction in an adolescent girl
60. Treatment of herpes simplex gingivostomatitis with aciclovir in children: A randomised double blind placebo controlled study
61. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial
62. Acyclovir prevents reactivation of herpes simplex labialis in skiers
63. Herpes simplex virus type 1 meningitis
64. Herpes simplex virus infection of the fetus and newborn
65. Prognostic factors in childhood acute encephalitis
66. Long term neurological outcome of herpes encephalitis
67. Perinatal herpes: Current status and obstetric management strategies
68. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: Results of a phase I/II trial
69. Perinatal herpes simplex infection presenting with pneumonia and pleural effusions
70. Emergency department evaluation and management of chickenpox
71. Children hospitalized for varicella: A prevaccine review
72. Management of varicella-zoster virus infections in children
73. Disseminated varicella in a neonate: Implications for immunoprophylaxis of neonates postnatally exposed to varicella
74. Deaths from varicella in infants
75. Recent corticosteroid use and the risk of complicated varicella in otherwise immunocompetent children
76. Acyclovir therapy of chickenpox in immunosuppressed children-A collaborative study
77. Intravenous acyclovir therapy for varicella in immunocompromised children
78. Congenital and neonatal varicella
79. Neonatal chickenpox
80. Treatment with acyclovir of varicella pneumonia in pregnancy
81. A controlled trial of acyclovir for chickenpox in normal children
82. Acyclovir treatment of varicella in otherwise healthy children
83. Oral acyclovir prophylaxis of varicella after intimate contact
84. Acyclovir treatment of varicella in otherwise healthy adolescents
85. Pediatric herpes zoster with mild cutaneous dissemination
86. Two cases of disseminated cutaneous herpes zoster in infants after intrauterine exposure to varicellazoster virus
87. Ramsay Hunt syndrome presenting as a cranial polyneuropathy
88. Valaciclovir A: Review of its use in the management of herpes zoster
89. Infectious mononucleosis
90. Infectious mononucleosis in young children
91. Mononucleosis caused by Epstein-Barr virus and cytomegalovirus in children: A comparative study of 124 cases
92. Sudden hearing loss caused by Epstein-Barr virus
93. Picture of the month. Facial nerve palsy secondary to Epstein-Barr virus infection
94. Acute manifestations and neurologic sequelae of Epstein-Barr virus encephalitis in children
95. Acute complications of Epstein-Barr virus infectious mononucleosis
96. Sinusitis, orbital cellulitis and polymicrobial bacteremia in a patient with primary Epstein-Barr virus infection
97. Viral infections in immunocompromised children
98. Effect of acyclovir on infectious mononucleosis: A double-blind, placebo-controlled study
99. Acyclovir treatment in infectious mononucleosis: A clinical and virological study
100. Lack of effect of peroral acyclovir for the treatment of acute infectious mononucleosis
101. Acyclovir for treatment of infectious mononucleosis: A meta-analysis
102. Acyclovir and prednisolone treatment of acute infectious mononucleosis: A multicenter, doubleblind, placebo-controlled study
103. Epstein-Barr virus associated aplastic anaemia and hepatitis
104. Cytomegalovirus infections
105. Human cytomegalovirus: Biology and clinical perspectives
106. Cytomegalovirus infection
107. Ganciclovir therapy for cytomegalovirus-associated liver disease in immunocompetent or immunocompromised children
108. Intractable diarrhea from cytomegalovirus enterocolitis in an immunocompetent infant
109. Ganciclovir treatment of cytomegalovirus disease in immunocompromised children
110. Ganciclovir for the treatment of disseminated CMV disease without pneumonia in allogeneic Tlymphocyte depleted bone marrow transplantation
111. Use of ganciclovir for cytomegalovirus infection
112. Screening for cytomegalovirus retinitis in children
113. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS
114. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS
115. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS
116. Treatment of bilateral cytomegalovirus retinitis with sustained-release ganciclovir implants in a child
117. Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis
118. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients with cytomegalovirus retinitis: AIDS clinical Trials Group Protocol 151
119. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial
120. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement
121. Enterovirus 71 infections at a Canadian center
122. Clinical significance of enteroviruses in serious summer febrile illnesses of children
123. Profile of enterovirus disease in the first two weeks of life
124. Management of central nervous system infections during an epidemic of enteroviral aseptic meningitis
125. Enterovirus infections
126. Fatal enterovirus type 71 infection: Rapid detection and diagnostic pitfalls
127. Severe neonatal echovirus 20 infection characterized by hepatic failure
128. Severe neonatal echovirus 17 infection during a nursery outbreak
129. Fatal enterovirus 71 encephalomyelitis
130. Neonatal enterovirus infection: Virology, serology, and effects of intravenous immune globulin
131. Successful treatment of enterovirus infection with the use of pleconaril in 2 infants with severe combined immunodeficiency
132. ViroPharma announces results of viral respiratory infection and viral meningitis studies
133. Single-dose pharmacokinetics of a pleconaril (VP63843) oral solution in children and adolescents. Pediatric Pharmacology Research Unit Network
134. Single dose pharmacokinetcs of pleconaril in neonates. Pediatric Pharmacology Research Unit Network